SPIE SA : Attractive timing to go long again
Entry price | Target | Stop-loss | Potential |
---|
€16.57 |
€17.8 |
€15.8 |
+7.42% |
---|
The fact that share price is returning to the lower bounds of the trading range offers a good timing to enter into new long positions in SPIE.
Summary● In a short-term perspective, the company has interesting fundamentals.
Strengths● The stock, which is currently worth 2019 to 0.56 times its sales, is clearly overvalued in comparison with peers.
● This company will be of major interest to investors in search of a high dividend stock.
● Sales forecast by analysts have been recently revised upwards.
● Analysts covering this company mostly recommend stock overweighting or purchase.
● The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses● The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.